Akebia Therapeutics: A Company Profile

Trending News 🌥️

Akebia Therapeutics ($NASDAQ:AKBA), Inc. is a commercial biopharmaceutical company that discovers, develops, and commercializes novel therapeutics for treating people impacted by kidney disease. The company was incorporated in 2007 and became a public company in 2014. It is headquartered in Cambridge, MA. Akebia is developing a pipeline of products that target the HIF pathway, which plays a role in regulating tissue oxygen levels. Akebia’s lead product, vadadustat, is an oral therapy that is currently in Phase 3 clinical trials for the treatment of anemia in patients with chronic kidney disease.

The company is also developing Auryxia, an oral iron chelator, which is approved in the United States for the treatment of iron deficiency anemia in adults with chronic kidney disease. In addition to its clinical-stage products, Akebia also has a pre-clinical pipeline of products targeting HIF. The company’s goal is to develop treatments that improve the lives of patients with kidney disease by providing novel therapies that target the underlying causes of the disease.

Market Price

Akebia Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of therapeutics for patients with kidney diseases. Akebia Therapeutics has been in the news recently mostly for negative reasons. The company is currently facing several lawsuits, including one from former employees who allege that they were fired because of their age. Akebia Therapeutics has also been accused of gender discrimination and of retaliation against employees who raised concerns about the company’s practices.

Despite the recent challenges, Akebia Therapeutics remains committed to their mission of developing treatments for patients with kidney diseases. They are currently working on several clinical trials and are hopeful that their efforts will eventually pay off.

VI Analysis

Akebia Therapeutics is a pharmaceutical company focused on the development and commercialization of treatments for anemia and kidney disease. The company’s fundamentals reflect its long term potential, with a strong focus on research and development, and a strong financial position.

However, Akebia Therapeutics has a low health score of 2/10 considering its cashflows and debt, which may limit its ability to sustain future operations in times of crisis. The company is classified as a “rhino”, meaning it has achieved moderate revenue or earnings growth. Investors interested in Akebia Therapeutics may be attracted to its strong fundamentals and potential for long-term growth.

Summary

Akebia Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of renal diseases. The company’s lead product candidate, vadadustat, is a first-in-class, oral therapy for the treatment of anemia in patients with chronic kidney disease . Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, Massachusetts. The company went public in 2014 and trades on the Nasdaq under the ticker symbol AKBA.

The company has been plagued by negative media exposure in recent months, with several articles published highlighting the company’s struggles. Despite this, the stock price has remained relatively stable.